Shots:

• Daiichi Sankyo to receive $1B as upfront of which $350M is due upon execution- $325M after 12mos. and $325M after 24 mos.- ~$5B as contingent payment including $1B as regulatory milestones- and $4B as commercial milestones- making a total deal value up to ~6B
• The companies will jointly develop and commercialize DS-1062 globally and share equal development & commercialization costs- except in Japan where Daiichi Sankyo will maintain exclusive rights and manufacture and supply DS-1062
• Daiichi Sankyo is expected to book sales in the US- certain EU countries- and other markets where the company has affiliates while AstraZeneca is expected to book sales in other markets globally- including China- Australia- Canada- and Russia. DS-1062 is a TROP2 directed DXd ADC- currently in P-I study for NSCLC and TNBC

­ Ref: Daiichi Sankyo | Image: Roots Analysis